Priftin

Company: Hoechst Marion Roussel
Approval Status: Approved June 1998
Treatment for: pulmonary tuberculosis
Areas: Respiratory

| General Information | Side Effects |

General Information

Priftin has been approved for the treatment of pulmonary tuberculosis. Priftin must always be used in conjunction with at least one other antituberculosis drug to which Mycobacterium tuberculosis is susceptible. Priftin should be administered twice weekly for two months, with an interval of no less than three days (72 hours) between doses, as part of an appropriate regimen which includes companion drugs.

Side Effects

The most common adverse events related to treatment with Priftin combination therapy include hyperuricemia, increased liver function tests, neutropenia, pyuria, proteinuria, and lymphopenia.

< back to top

Priftin Drug Information

The Priftin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.